IL-1-receptor Antagonist During Cephalic Phase of Insulin Secretion in Health and Type 2 Diabetes

NCT04227769 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

18

Enrollment

OTHER

Sponsor class

Stopped Too low recruitment in group with patients with diabetes.

Conditions

Diabetes Mellitus Type 2 in Obese
Inflammation
Metabolic Disease
Glucose Metabolism Disorders (Including Diabetes Mellitus)

Interventions

DRUG: Anakinra Prefilled Syringe

Sponsor

University Hospital, Basel, Switzerland